Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 10 of 10 publications.

George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w

Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7

Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3

Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x

Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4

Calderwood MS, Kawai AT, Jin R, Lee GM. Centers for medicare and medicaid services hospital-acquired conditions policy for central line-associated bloodstream infection (CLABSI) and cather-associated urinary tract infection (CAUTI) shows minimal impact on hospital reimbursement. Infect Control Hosp Epidemiol. 2018 Aug;39(8):897-901. doi: 10.1017/ice.2018.137

Hsu HE, Kawai AT, Wang R, Jentzsch MS, Rhee C, Horan K, Jin R, Goldmann D, Lee GM. The impact of the Medicaid healthcare-associated condition program on mediastinitis following coronary artery bypass graft. Infect Control Hosp Epidemiol. 2018 Jun;39(6):694-700. doi: 10.1017/ice.2018.69

Calderwood MS, Vaz LE, Tse Kawai A, Jin R, Rett MD, Grant PS, Lee GM. Impact of hospital operating margin on central line-associated bloodstream infections following Medicare's hospital-acquired conditions payment policy. Infect Control Hosp Epidemiol. 2016 Jan;37(1):100-3. doi: 10.1017/ice.2015.250

Kawai AT, Calderwood MS, Jin R, Soumerai SB, Vaz LE, Goldmann D, Lee GM. Impact of the Centers for Medicare and Medicaid Services hospital-acquired conditions policy on billing rates for 2 targeted healthcare-associated infections. Infect Control Hosp Epidemiol. 2015 Aug;36(8):871-7. doi: 10.1017/ice.2015.86

Vaz LE, Kleinman KP, Kawai AT, Jin R, Kassler WJ, Grant PS, Rett MD, Goldmann DA, Calderwood MS, Soumerai SB, Lee GM. Impact of Medicare's Hospital-Acquired Condition policy on infections in safety net and non-safety net hospitals. Infect Control Hosp Epidemiol. 2015 Jun;36(6):649-55. doi: 10.1017/ice.2015.38.